Loading ...Moderna drops, Arbutus pops after patent ruling means vaccine maker could owe royalties on billions in COVID shot revenue
- Moderna stock fell 11% on Wednesday after the vaccine maker lost a patent fight against Arbutus Biopharma.
- Arbutus jumped 103% following the ruling as it could lead to royalty payments from Moderna.
- Moderna’s COVID-19 vaccine is expected to generate about $20 billion in revenue this year and next.